Plant Name: Spatholobus suberectus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GPBAR1; | |
| ALPL; RECQL; TDP1; BLM; GLO1; HPGD; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; AKR1B10; ALDH1A1; ALOX12; NOX4; TNKS; PARP1; TNKS2; APEX1; POLB; CD38; AOX1; | |
| MGAM; GAA; | |
| CSNK2A1; FLT3; ABL1; GSK3B; MAPK1; EGFR; PIM1; LCK; FYN; | |
| CA12; CA5B; CA3; CA14; CA7; CA1; CA9; CA4; CA6; CA2; CA5A; | |
| NR1H4; | |
| ESRRB; ESRRA; | |
| PPARA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALDH2; ALOX5; XDH; | |
| ELANE; | |
| MMP12; MMP2; MMP9; | |
| BACE1; | |
| HIF1A; NFKB1; TP53; | |
| FUT7; | |
| ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; MAPT; THPO; HTT; RAB9A; NPC1; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.251E-13 | 1.238E-10 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.306E-13 | 4.033E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.046E-11 | 7.346E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.335E-10 | 1.452E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.330E-10 | 1.813E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.133E-10 | 2.589E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.575E-09 | 1.112E-06 | ABL1, CA2, CA7, CD38, EGFR, FYN, HIF1A, HTT, LCK, MAPK1, NPC1, NR1H4, PARP1, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 5.329E-09 | 1.568E-06 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1, NR1H4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.403E-09 | 1.811E-06 | ABL1, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPC1, NR1H4, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.361E-08 | 7.869E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.885E-08 | 8.813E-06 | ABCG2, AOX1, APP, BLM, CD38, CSNK2A1, EGFR, ESR1, ESR2, FLT3, FYN, HPGD, HTT, LCK, MAPK1, MAPT, MMP9, NFKB1, PARP1, RAB9A, SMN1, SMN2, TP53, TTR, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.936E-07 | 3.641E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.936E-07 | 3.641E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.701E-07 | 4.943E-05 | ABL1, AKR1B1, ALOX12, CD38, CSNK2A1, EGFR, FYN, GLO1, GSK3B, HIF1A, HTT, LMNA, MMP9, NFKB1, NR1H4, PIM1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.643E-07 | 6.246E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.142E-07 | 1.029E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.019E-07 | 1.167E-04 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.376E-06 | 2.096E-04 | ABL1, FYN, GSK3B, MAPT, PARP1, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.118E-06 | 2.957E-04 | CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| MF | GO:0005488; binding | GO:0051287; NAD binding | 7.217E-06 | 8.541E-04 | ALDH1A1, ALDH2, AOX1, HPGD, PARP1 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 7.525E-06 | 8.809E-04 | APP, EGFR, MAPT |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 7.525E-06 | 8.809E-04 | BLM, RECQL, TP53 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 9.204E-06 | 1.028E-03 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.152E-05 | 1.248E-03 | CYP1A2, EGFR, MAPK1, MMP9 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.468E-05 | 1.575E-03 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.521E-05 | 1.608E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4, PIM1, PPARA |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.677E-05 | 1.756E-03 | BLM, GSK3B, HIF1A, HTT, TP53 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.737E-05 | 1.801E-03 | ABL1, APEX1, CA5A, CA5B, CYP1A1, CYP1B1, CYP2D6, ESR2, FYN, GSK3B, HSD17B10, MAOA, MAPK1, MMP2, NFKB1, NOX4, PARP1, TP53 |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.796E-05 | 1.853E-03 | AKR1B10, ALDH1A1, ALDH2, AOX1, BACE1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, ELANE, FUT7, GAA, GSK3B, HSD17B10, MAOA, MGAM, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 2.052E-05 | 2.022E-03 | AOX1, XDH |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.052E-05 | 2.022E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.052E-05 | 2.022E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.052E-05 | 2.022E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.052E-05 | 2.022E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 2.052E-05 | 2.022E-03 | FYN, LCK |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 2.185E-05 | 2.143E-03 | CD38, CYP1A2, EGFR, ESR1, ESRRA, HPGD |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.389E-05 | 2.312E-03 | CD38, CYP1A1, HIF1A, LMNA, MMP2, NOX4, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.528E-05 | 2.436E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.855E-05 | 2.712E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4, PPARA |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 3.263E-05 | 3.050E-03 | ABL1, ALOX12, APP, EGFR, ELANE, HIF1A, MAPK1, MMP9, NOX4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.855E-05 | 3.512E-03 | ABL1, ALPL, CYP1A1, CYP1A2, ELANE, HPGD, NFKB1, NR1H4 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.606E-05 | 4.111E-03 | ABL1, CA2, CA7, FYN, HTT, LCK, PARP1 |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 4.780E-05 | 4.231E-03 | ABL1, APP, CA2, CD38, ELANE, FYN, HIF1A, LCK, MAPK1, MMP12, MMP2, NFKB1, NR1H4, THPO, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 5.149E-05 | 4.466E-03 | ABL1, ALOX12, APP, CA2, CD38, CYP1B1, EGFR, ELANE, ESRRB, FYN, HIF1A, MAPT, MMP12, MMP9, NFKB1, NR1H4, PARP1, PIM1, THPO |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 5.671E-05 | 4.843E-03 | EGFR, MAPT, NOX4, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.933E-05 | 4.961E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.138E-05 | 4.961E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 6.138E-05 | 4.961E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 6.138E-05 | 4.961E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.138E-05 | 4.961E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.138E-05 | 4.961E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.138E-05 | 4.961E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.138E-05 | 4.961E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 6.138E-05 | 4.961E-03 | GAA, MGAM |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.138E-05 | 4.961E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.138E-05 | 4.961E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.176E-05 | 4.963E-03 | ABL1, EGFR, FYN, LCK |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 6.379E-05 | 5.107E-03 | ALPL, CA2, CD38, EGFR, FLT3, NPC1, PARP1 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 6.863E-05 | 5.454E-03 | ABL1, APP, CSNK2A1, CYP1B1, CYP2D6, ESR1, GSK3B, MAPT, MMP9, NFKB1, NR1H4, PIM1, PPARA, RAB9A, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 9.101E-05 | 6.929E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4, PPARA |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 9.207E-05 | 6.985E-03 | APEX1, EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, NFKB1, NR1H4, PARP1, PPARA, TDP1, TP53 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 9.767E-05 | 7.359E-03 | ABL1, CYP1B1, GSK3B, HPGD, HTT, LCK, MAPT, MMP9, NOX4, TP53, XDH |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 9.848E-05 | 7.369E-03 | EGFR, ESRRB, HIF1A |
| CC | GO:0043226; organelle | GO:0000242; pericentriolar material | 9.848E-05 | 7.369E-03 | LCK, TNKS, TNKS2 |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 9.921E-05 | 7.376E-03 | APP, EGFR, FYN, HIF1A, HTT, MAPK1, MAPT |
| MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1.023E-04 | 7.524E-03 | ESR1, ESRRA, ESRRB, HIF1A, NFKB1, NR1H4, PARP1, PPARA, TP53 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.043E-04 | 7.644E-03 | EGFR, LCK, MAPK1, MAPT, PPARA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.069E-04 | 7.784E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.145E-04 | 8.284E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.152E-04 | 8.305E-03 | ABL1, FLT3, HIF1A, LCK, MAPK1, POLB |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.224E-04 | 8.620E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.224E-04 | 8.620E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.227E-04 | 8.620E-03 | ABL1, APEX1, APP, BLM, CD38, CSNK2A1, CYP2D6, ELANE, ESR1, ESR2, ESRRA, FYN, GSK3B, HIF1A, MAPT, MMP12, MMP9, NFKB1, NPC1, NR1H4, PARP1, PPARA, TNKS, TNKS2, TP53, XDH |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.224E-04 | 8.620E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 1.224E-04 | 8.620E-03 | GAA, MGAM |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.322E-04 | 9.136E-03 | HPGD, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.234E-23 | 8.957E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.234E-17 | 2.262E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.245E-16 | 1.142E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.525E-14 | 1.953E-11 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.579E-23 | 1.417E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.877E-11 | 6.430E-09 | MAOA; ALOX15; AKR1B1; ALOX12; CYP2C19; CYP3A4; CYP19A1; HSD17B10; FUT7; ALDH2; HSD17B1; ALOX5; HSD17B2; CD38; AOX1; XDH; MGAM; GAA; CYP2C9; AKR1B10; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; ALPL |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.544E-09 | 9.625E-08 | CYP2C9; APP; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.078E-08 | 6.752E-07 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.278E-09 | 2.935E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.166E-08 | 6.752E-07 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.305E-08 | 2.219E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.080E-07 | 6.399E-06 | CYP2C9; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.095E-07 | 7.657E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.205E-07 | 1.279E-05 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.952E-07 | 1.182E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.606E-07 | 3.755E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.653E-06 | 1.062E-04 | GSK3B; FLT3; MMP2; ABL1; MAPK1; HIF1A; TP53; MMP9; EGFR; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.930E-06 | 6.146E-05 | MMP2; MAPK1; ESR1; MMP9; EGFR; ESR2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.724E-07 | 1.399E-05 | MMP2; MAPK1; MMP9; TP53; EGFR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.635E-06 | 2.184E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.170E-05 | 2.695E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.631E-05 | 1.605E-04 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.146E-05 | 1.190E-04 | FLT3; MAPK1; TP53; HIF1A; EGFR |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.677E-05 | 2.503E-04 | GSK3B; MAPK1; PPARA; TP53; EGFR; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.036E-05 | 2.695E-04 | GSK3B; CSNK2A1; RAB9A; FYN; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.945E-05 | 3.853E-04 | PIM1; ABL1; CYP1B1; MAPK1; TP53; MMP9; EGFR; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.563E-05 | 3.710E-04 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.601E-05 | 6.825E-04 | GSK3B; LCK; MAPK1; FYN; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.855E-05 | 6.825E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.438E-04 | 9.274E-04 | HPGD; FLT3; TP53; MMP9; ELANE; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.741E-04 | 1.085E-03 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.883E-04 | 1.109E-03 | GSK3B; ABL1; MAPK1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.062E-05 | 6.030E-04 | GSK3B; MAPK1; TP53; EGFR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.786E-06 | 1.027E-04 | MGAM; AKR1B10; GAA; AKR1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.157E-04 | 7.726E-04 | FLT3; PIM1; MAPK1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.846E-04 | 1.998E-03 | PARP1; LMNA; MAPK1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.048E-04 | 1.161E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.021E-04 | 1.662E-03 | ABL1; MAPK1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.032E-03 | 4.708E-03 | MMP2; PIM1; MAPK1; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.183E-04 | 1.701E-03 | CSNK2A1; MAPK1; FYN; EGFR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.897E-04 | 2.827E-03 | GSK3B; ABL1; MAPK1; EGFR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.988E-03 | 8.084E-03 | GSK3B; CSNK2A1; CD38; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.110E-03 | 4.944E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 7.581E-04 | 3.544E-03 | CSNK2A1; PARP1; LCK; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.950E-03 | 8.084E-03 | MAPK1; FYN; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.756E-03 | 1.031E-02 | LCK; MAPK1; FYN; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.396E-03 | 9.336E-03 | GSK3B; ABL1; MAPK1; FYN |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.954E-03 | 1.369E-02 | MAPK1; TP53; MMP9; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.376E-03 | 1.733E-02 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 5.644E-03 | 1.789E-02 | POLB; GSK3B; LCK; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.928E-03 | 8.084E-03 | MAPK1; TP53; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.791E-03 | 1.338E-02 | MAPK1; TP53; EGFR |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.100E-03 | 1.394E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.953E-03 | 1.062E-02 | MAPK1; TP53; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.158E-02 | 3.139E-02 | MAPK1; PPARA; NFKB1; TSHR |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.218E-02 | 3.255E-02 | GSK3B; MAPK1; FYN; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.581E-03 | 9.850E-03 | GSK3B; MAPK1; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.280E-02 | 3.279E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.006E-02 | 2.850E-02 | MAPK1; HIF1A; EGFR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.567E-03 | 2.211E-02 | MMP2; MAPK1; EGFR |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.240E-03 | 8.911E-03 | AKR1B10; ALDH2; AKR1B1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.734E-02 | 4.137E-02 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 6.900E-03 | 2.115E-02 | THPO; FLT3; CD38 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.236E-02 | 3.255E-02 | GSK3B; PPARA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.266E-02 | 3.279E-02 | MAPK1; MMP9; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.796E-02 | 4.197E-02 | ABL1; MAPK1; EGFR; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.669E-02 | 4.106E-02 | TBXAS1; MAPK1; FYN |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.953E-03 | 1.062E-02 | ABL1; MAPK1; NFKB1 |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 1.234E-03 | 5.366E-03 | ALDH2; AOX1; HSD17B10 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.528E-02 | 3.809E-02 | ALOX5; MAPK1; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.742E-02 | 4.137E-02 | GSK3B; ABL1; TP53 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.176E-02 | 4.904E-02 | LCK; MAPK1; FYN |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.291E-04 | 2.604E-03 | AKR1B10; ALDH2; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.082E-04 | 2.063E-03 | POLB; PARP1; APEX1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.045E-02 | 4.664E-02 | ALDH2; MAOA |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.969E-02 | 4.545E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.748E-02 | 4.137E-02 | CYP3A4; XDH |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.036E-02 | 2.850E-02 | MAPK1; FYN |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.194E-03 | 2.135E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 6.255E-03 | 1.949E-02 | MAPK1; EGFR |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.340E-02 | 3.385E-02 | ALDH2; GLO1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.036E-02 | 2.850E-02 | MAOA; AOX1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 8.714E-03 | 2.507E-02 | AKR1B10; AKR1B1 |
| hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 7.194E-03 | 2.135E-02 | AOX1; CD38 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.560E-03 | 1.523E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 4.961E-03 | 1.627E-02 | ALDH2; MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.898E-04 | 1.109E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESRRA; MMP2; ESR1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; CA9; ABL1; MMP2; HIF1A; MAPK1; MMP9; EGFR; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA; ALOX5; ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; EGFR; EGFR; TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; ELANE; MMP12 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; CA1; FLT3; FLT3; CA9; ABL1; MMP2; CD38; GSK3B; HIF1A; MAPK1; MMP9; NFKB1; EGFR; PIM1; PARP1; TP53; ESR1; ESR1; APP |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM; NFKB1; GPBAR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; CYP19A1; EGFR; EGFR; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ABL1; EGFR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; GSK3B; APP |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; ALOX5 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; MMP2; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A; EGFR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ELANE; ELANE; MMP12; MMP12 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | CD38; TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA; ALOX5; ALOX5; ELANE; MMP12 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE; PARP1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |